Medical HIGH

Arkansas

Arkansas operates a tightly regulated, limited-license medical cannabis program (Tier 3) initiated by voters in 2016, with adult-use remaining strictly prohibited.
The state set a new medical cannabis sales record in 2025, reaching $291.1 million and bringing cumulative sales since the program's inception to over $1.6 billion.
Adult-use legalization (Issue 4) failed significantly at the ballot box in 2022, facing a coalition of conservative opposition and progressive dissatisfaction over a lack of social equity and expungement provisions.
In 2024, the Arkansas Supreme Court disqualified Issue 3, a ballot measure designed to drastically expand the medical program, ruling its ballot title misleading just weeks before the election.
The state maintains some of the harshest criminal penalties for illicit cannabis possession and distribution in the United States, alongside significant, persistent racial disparities in arrest rates.
Cross-border dynamics are complex; while neighboring Missouri offers legal adult-use and Oklahoma provides an accessible medical market with temporary out-of-state cards, Arkansas law enforcement and state officials continuously warn against the federal and state illegality of interstate transport.

Arkansas, located in the southern region of the United States, represents a complex intersection of deeply conservative political governance and a highly lucrative, rapidly expanding medical cannabis market. As of 2025, the estimated population of Arkansas stands at approximately 3.11 million residents. The state's political apparatus is dominated by the Republican Party, which holds supermajorities in the Arkansas General Assembly (the state legislature). The executive branch is led by Governor Sarah Huckabee Sanders (Republican), who has maintained a stringent stance on drug policy and public safety. The state's top law enforcement official is Attorney General Tim Griffin, whose stance on cannabis and related cannabinoid products is decidedly prohibitionist. Attorney General Griffin has been highly active in leveraging the judicial system to block the expansion of cannabis access and the proliferation of unregulated cannabinoids. In 2024, he co-led a 20-state bipartisan coalition urging the United States Congress to affirm states' authority to ban or heavily regulate intoxicating hemp-derived products, such as Delta-8 THC, under the upcoming Farm Bill. Furthermore, his office successfully defended Act 629 of 2023, which explicitly banned psychoactive hemp products, winning a reversal in the United States Court of Appeals for the Eighth Circuit against industry plaintiffs. Griffin's office was also instrumental in the legal challenges that ultimately derailed the 2024 medical cannabis expansion ballot measure (Issue 3). This political environment underscores the fundamental tension in Arkansas: a populace that has repeatedly shown a willingness to embrace medical cannabis via direct democracy, juxtaposed against a political leadership structurally opposed to the normalization, expansion, or adult-use legalization of the plant.

Medical

Medical Program

Medical Status: Legal — Limited License Medical Program (Amendment 98, 2016). Regulated by Arkansas Department of Health (patient registration) and Alcoholic Beverage Control Division (dispensaries/cultivators).^[6]

Despite its restrictive framework, the Arkansas medical cannabis market is robust, demonstrating consistent year-over-year growth in patient participation, product volume moved, and state tax revenue generated. In 2025, Arkansas dispensaries recorded a record-breaking $291.1 million in medical cannabis sales, representing a 5.5% increase from the $275.9 million generated in 2024, and surpassing the previous peak of $283 million established in 2023. Since the launch of the commercial market in May 2019, cumulative sales have eclipsed $1.6 billion. The patient base has expanded steadily. By December 2025, the Arkansas Department of Health reported 115,113 active medical cannabis patient cards, an 18.2% increase compared to the 97,374 active patients reported at the beginning of 2024. The most prevalent qualifying condition is PTSD (nearly 35%), followed by intractable pain (29%) and severe arthritis (11.5%). Arkansas maintains a strict cap on the number of medical cannabis licenses, structurally fostering an oligopolistic market environment. The state constitution caps dispensary licenses at 40, distributed across eight geographic zones, with 37 actively operating. The state is limited to 8 licensed cultivation facilities, all currently in operation. Arkansas imposes a bifurcated, relatively high tax burden on medical cannabis. A standard 6.5% sales tax is applied to every retail purchase, plus a 4% special privilege tax levied twice in the supply chain. In 2025, these taxes generated $32.3 million in revenue, with cumulative state medical cannabis taxes exceeding $218.3 million since 2019.

Penalties (Outside Medical Program)

Offense	Amount	Classification	Penalty
Misdemeanor Possession	Less than 4 ounces (first offense)	Class A Misdemeanor	Up to 1 year in jail, up to $2,500 fine. Mandatory 6-month driver's license suspension for any cannabis conviction. ^[9]
Felony Possession (Repeat Offender)	1 ounce to less than 4 ounces (4+ prior convictions for Schedule VI possession)	Class D Felony	Up to 6 years incarceration, $10,000 fine ^[5]
Felony Possession	4 ounces to less than 10 pounds	Class D Felony	Up to 6 years incarceration, $10,000 fine ^[5]
Felony Possession	10 pounds to less than 25 pounds	Class C Felony	Mandatory minimum 3 years, up to 10 years, $10,000 fine ^[5]
Trafficking	500 pounds or more	Class Y Felony	10 to 40 years or life in prison ^[9]
Cultivation/Delivery	14 grams or less	Class A Misdemeanor	Up to 1 year in jail, up to $2,500 fine ^[9]
Cultivation/Delivery	14 grams to 4 ounces	Class D Felony	Up to 6 years incarceration, $10,000 fine ^[9]

Criminal Justice

Group	Metric	Value
Black	National Disparity Ratio (applicable to Arkansas)	3.64x more likely to be arrested for cannabis possession than white people despite roughly equivalent usage rates ^[24]

The enforcement of cannabis prohibition in Arkansas reflects broader national trends of significant racial disparities. According to comprehensive data analyzed by the ACLU relying on the FBI's Uniform Crime Reporting Program, despite roughly equivalent usage rates across racial demographics, Black people are 3.64 times more likely to be arrested for cannabis possession than white people. While ACLU data from 2010 to 2018 indicated that some national arrest volumes declined marginally, the disparity gap did not close and, in many jurisdictions, worsened. Arkansas was explicitly noted in separate academic analyses as a state that structurally increased penalties for cannabis possession during certain legislative periods, ensuring that minor offenses continue to carry severe lifelong consequences. Arkansas does not provide automatic expungement or blanket record relief for past cannabis offenses, meaning the burden rests entirely on the individual to navigate the judicial system. Under specific state statutes, a first-time offender pleading guilty to misdemeanor possession may be placed on probation for at least one year, and upon successful completion, the court may dismiss the case and expunge the record. Efforts to mandate broad record relief have stalled, including a 2020 ballot initiative that failed to gather sufficient signatures and the 2022 Issue 4 which explicitly omitted expungement provisions.

What Arkansas Is Leaving on the Table

If Arkansas had adult-use cannabis sales at the level of operational states:

Benchmark	Per Capita	Rank	Estimated AR Market
Connecticut (#20)	$60.73	Lowest	$189M
New Jersey (#15)	$126.23	Mid-pack	$393M
Colorado (#9)	$196.26	Mature	$610M

Based on total state population and per capita sales from operational markets. Actual results vary by market design, tax structure, licensing speed, and border dynamics. See how all 20 legal states compare →

Borders

Border Dynamics

Neighbor	Legal Status	Notes
Missouri	Adult-use legal (Amendment 3, 2022)	—
Oklahoma	Liberal medical cannabis program with thousands of dispensaries	—
Tennessee	Fully prohibited (medical CBD only)	—
Mississippi	Medical only (2022)	—
Louisiana	Medical only / limited adult-use	—
Texas	Highly restricted medical (Compassionate Use Program)	—

Arkansas shares highly porous borders with two states that possess drastically different cannabis regulatory environments, creating intense economic leakage and legal hazards for residents. Missouri legalized adult-use cannabis in 2022 via Amendment 3, creating a massive, accessible retail market directly on Arkansas's northern border. Oklahoma operates one of the most liberal, free-market medical cannabis programs in the country, boasting thousands of dispensaries, rock-bottom retail pricing due to market saturation, and an incredibly low barrier to entry. The disparity in pricing and access has led to significant cross-border dynamics. Oklahoma expressly extends reciprocity to out-of-state patients; an Arkansas resident with a valid Arkansas medical cannabis card can apply online for a 30-day temporary Oklahoma license, allowing them to purchase product at drastically lower prices. Similarly, the opening of adult-use retail stores in southern Missouri attracts Arkansans lacking medical cards. However, this practice carries severe legal risks. State officials have publicly warned that purchasing cannabis out of state and transporting it into Arkansas violates both federal interstate commerce laws and state law. Arkansas's Amendment 98 explicitly mandates that all medical cannabis consumed by Arkansas patients must be cultivated and processed within Arkansas's state boundaries. A patient caught bringing Missouri adult-use or Oklahoma medical cannabis into Arkansas loses their state-level legal protections and faces potential federal trafficking or state felony charges. Despite these laws, enforcement via dedicated border checkpoints is generally considered impractical.

Economic

Economic Opportunity

The economic footprint of cannabis in Arkansas is currently constrained by its medical-only status, but it remains a highly lucrative sector for the limited entities allowed to participate. The current Arkansas medical market generates roughly $350 million annually in total economic throughput, anchored by $291.1 million in direct retail sales in 2025. The state relies on the steady revenue stream provided by the medical sector, with the 6.5% sales tax and 4% privilege tax reliably generating between $31 million and $32.5 million annually ($32.3 million in 2025). Projections surrounding the failed 2022 adult-use initiative estimated that full legalization would have generated $2.36 billion to the state's GDP over a five-year period, alongside $303 million in supplemental tax receipts designated for law enforcement and infrastructure.

Political

Political Trajectory

The defeat of Issue 4 in 2022 provides a masterclass in the political complexities of Southern cannabis policy. The initiative failed by a definitive margin (56% opposed to 44% in favor), passing in only 6 of the state's 75 counties. Several factors converged to defeat the measure: the initiative was heavily bankrolled by the state's existing medical cannabis oligopoly with organizations raising over $14 million; it explicitly lacked expungement provisions alienating progressive voters; and relentless conservative messaging eroded initial 58.5% polling support to just 50.5%. Following the defeat of adult-use, advocates formed 'Arkansans for Patient Access' to push Issue 3 in 2024, seeking to liberalize the medical program by allowing telemedicine, home cultivation of up to 14 plants, and enacting a trigger law for automatic adult-use if federal descheduling occurred. Despite submitting over 150,000 signatures, the Arkansas Supreme Court ruled 4-3 to invalidate the measure on October 21, 2024, just as early voting began, finding the ballot title misleading. The political trajectory heavily favors the status quo. The combination of an entrenched, anti-cannabis executive branch, a conservative supreme court willing to aggressively scrutinize the citizen initiative process, and a deep-pocketed but politically polarizing medical oligopoly makes near-term adult-use legalization highly unlikely.